Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug ...

Israeli researchers discover that better glycemic control can improve overall health of the brain and slow age-related ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with ...

Gene therapy for Spinal Muscular Atrophy (SMA) is prohibitively expensive in India, with the life-saving drug Zolgensma ...

Immunis, Inc., a clinical-stage biotech developing novel secretomes for age-related diseases and immune dysfunction, has ...

MRI has shown that increases in the white matter of the brain and ventricle volume may be risk factors for the progression of ...

"With the support of our shareholders at the General Meeting, we are targeting an official close of the transaction on November 13, 2024 and will begin executing against the strategy for the combined ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

A study reveals that Mediterranean and green-MED diets rich in polyphenols may slow brain aging and reduce neurodegeneration through improved glycemic control.

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

Astellas Pharma Inc. has withdrawn its marketing authorization application from the EMA for its avacincaptad pegol intravitreal solution for the treatment of geographic atrophy secondary to ...

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).